Dirven, Linda and Luerding, Ralf and Beier, Dagmar and Bumes, Elisabeth and Reinert, Christiane and Seidel, Clemens and Bonsanto, Matteo Mario and Bremer, Michael and Rieken, Stefan and Combs, Stephanie E. and Herrlinger, Ulrich and Seliger, Corinna and Kuntze, Holger and Mayer-Steinacker, Regine and Dieing, Annette and Bartels, Claudius and Schnell, Oliver and Weyerbrock, Astrid and Seidel, Sabine and Grauer, Oliver and Nadji-Ohl, Minou and Paulsen, Frank and Weller, Michael and Wick, Wolfgang and Hau, Peter (2020) Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. JOURNAL OF NEURO-ONCOLOGY, 148 (1). pp. 117-130. ISSN 0167-594X, 1573-7373
Full text not available from this repository. (Request a copy)Abstract
Background Combined radiochemotherapy followed by maintenance chemotherapy with cisplatin, lomustine and vincristine within the NOA-07 study resulted in considerable short-term toxicity in adult medulloblastoma patients. Here we investigated the long-term impact of this treatment, focusing on neurocognitive functioning and health-related quality of life (HRQoL). Methods Neurocognitive functioning and HRQoL scores over time were determined, and differences between the post-treatment and follow-up assessments were calculated up to 18 months for neurocognition and 60 months for HRQoL. Results 28/30 patients were analyzed. The three preselected HRQoL scales (role, social and cognitive functioning) showed improved scores, to a clinically relevant extent (>= 10 points), compared to post-treatment levels up to 30 months, but decreased afterwards. Z-scores for verbal working memory were worse during follow-up compared to post-treatment scores and remained impaired during 18 months follow-up (i.e. z-score below - 1 standard deviation). Attention was impaired post-treatment, and remained impaired to a clinically relevant extent during follow-up. Coordination/processing speed and lexical verbal fluency improved compared to post-treatment scores, and remained within the normal range thereafter. Other tests of verbal fluency were stable over time, with z-scores within the normal range. Conclusions This long-term follow-up study showed that the NOA-07 treatment regimen was not associated with a deterioration in HRQoL in the post-treatment period. Verbal working memory deteriorated, while other neurocognitive domains did not seem to be impacted negatively by the treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LOW-GRADE GLIOMAS; PHASE-III; PEDIATRIC MEDULLOBLASTOMA; RADIOTHERAPY; IMPACT; QUESTIONNAIRE; CHEMOTHERAPY; BEVACIZUMAB; VALIDATION; SURVIVORS; Brain tumor; Medulloblastoma; Cognition; Quality of life; Patient-reported outcome; Toxicity |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 24 Mar 2021 11:55 |
| Last Modified: | 24 Mar 2021 11:55 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44606 |
Actions (login required)
 |
View Item |
